CN110577991A - Diagnosis box for non-obstructive azoospermia - Google Patents
Diagnosis box for non-obstructive azoospermia Download PDFInfo
- Publication number
- CN110577991A CN110577991A CN201910897201.9A CN201910897201A CN110577991A CN 110577991 A CN110577991 A CN 110577991A CN 201910897201 A CN201910897201 A CN 201910897201A CN 110577991 A CN110577991 A CN 110577991A
- Authority
- CN
- China
- Prior art keywords
- reagent
- sox30
- noa
- methylation
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
In the application, the methylation state of the SOX30 gene, the expression level of mRNA and encoded protein in normal control OA and NOA puncture testis tissues are detected, and the detection result shows that the SOX30 gene is subjected to specific hypermethylation and expression silencing in the NOA puncture testis tissues. Based on the detection result, the diagnosis box for the non-obstructive azoospermia is provided, and can help clinical NOA patients to make an effective treatment scheme, so that accuracy and treatment progress are improved, and meanwhile, the diagnosis box has important significance in better understanding of NOA pathogenic reasons, making risk assessment and early diagnosis.
Description
Technical Field
The application relates to the technical field of molecular biology, in particular to a diagnosis kit for non-obstructive azoospermia.
background
infertility, as an important disease affecting human proliferation, has become a serious medical health problem and a serious social problem worldwide and is receiving wide attention from people. The World Health Organization (WHO) predicts that infertility will become the third largest disease after tumor and cardiovascular disease in diseases affecting human life and Health. According to the latest statistical data of WHO, the number of couples suffering from infertility in the world is about 8000 ten thousand pairs, wherein male patients account for about 50 percent, and the proportion of infertility caused by male reasons is in an increasing situation year by year. In China, the male sterility problem is particularly prominent along with the opening of the national policy of 'two children'. The etiology of male infertility is very complex, and the pathological mechanism is not clear. Although some male infertility is caused by known causes such as Obstructive Azoospermia (OA), cryptorchism, varicocele, and the like, most male infertility is diagnosed as Non-obstructive azoospermia (NOA) of unknown cause.
At present, the diagnosis procedure for NOA patients is complex, semen routine analysis, semen biochemistry, blood hormone analysis, testis morphology analysis, testis puncture pathology analysis and the like need to be carried out, the detection processes are time-consuming and labor-consuming, and the illness state and treatment progress of the patients are seriously influenced. Therefore, a diagnostic kit that can rapidly and accurately diagnose NOA disease is in great demand.
Disclosure of Invention
The application provides a diagnosis box for non-obstructive azoospermia to solve the problems that the existing NOA detection process is time-consuming and labor-consuming, and the illness state and the treatment progress of a patient are seriously influenced.
The application provides a diagnostic kit for non-obstructive azoospermia, which comprises a reagent A for detecting the methylation state of the SOX30 gene,
The reagent A comprises a reagent A1 and a reagent A2, wherein the reagent A1 is used for amplifying a methylation product, and the reagent A1 comprises a pair of methylation primers, and the primer sequences of the methylation primers are respectively as follows:
SOX30F-M:TGG GTA GTA GTT ATG GAG TTT TTT TC，
SOX30R-M:CTC TAA CTT CAC CTA CAA CAA CCG；
the reagent A2 is used for amplifying unmethylated products, and the reagent A2 comprises a pair of unmethylated primers, wherein the primer sequences of the unmethylated primers are respectively:
SOX30F-U:TGG GTA GTA GTT ATG GAG TTT TTT TT，
SOX30R-U:CTC TAA CTT CAC CTA CAA CAA CCA C。
Optionally, the diagnostic kit further comprises a reagent B, wherein the reagent B is a primer pair for detecting the expression level of the gene SOX30, the primer pair is used for RT-PCR for amplifying a SOX30 specific fragment, and the primer sequences of the primer pair are respectively as follows:
SOX30F:GAT GTC CCG CTC ACC GTG TTG C,
SOX30R:GAC AGG GCT TGG GCT CTG GAC T。
Optionally, the diagnostic kit further comprises a reagent C, wherein the reagent C is a reagent for detecting the content of the SOX30 protein.
alternatively, the reagent C is a monoclonal antibody to SOX30 protein.
In the application, the methylation state of the SOX30 gene, the expression level of mRNA and encoded protein in normal control OA and NOA puncture testis tissues are detected, and the detection result shows that the SOX30 gene is subjected to specific hypermethylation and expression silencing in the NOA puncture testis tissues. Based on the detection result, the diagnosis box for the non-obstructive azoospermia is provided, and can help clinical NOA patients to make an effective treatment scheme, so that accuracy and treatment progress are improved, and meanwhile, the diagnosis box has important significance in better understanding of NOA pathogenic reasons, making risk assessment and early diagnosis.
Drawings
In order to more clearly explain the technical solution of the present application, the drawings needed to be used in the embodiments will be briefly described below, and it is obvious to those skilled in the art that other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 shows the identification of SOX30 as an important methylated gene in NOA by methylation sequencing, wherein left to right represents the entire chromosome narrowing to chromosome five and the relocation to the SOX30 gene;
FIG. 2 is a graph of the methylation of SOX30 in OA and NOA-punctured testis tissue, wherein U represents the unmethylated product (shown as the band in the graph) and M represents the methylated product (shown as the band in the graph);
FIG. 3 shows the mRNA expression of SOX30 in OA and NOA-punctured testis tissue, where ACTIN stands for β -ACTIN;
FIG. 4 shows the protein expression of SOX30 in OA and NOA punctured testis tissue, wherein the brown-yellow color represents SOX30 expression staining.
Detailed Description
The SOX family is a type of developmental nuclear transcription factor, and is a gene superfamily consisting of male sex determining gene SRY (sexing region of Chr Y) related genes, and the members of the gene superfamily have highly conserved DNA binding domains (HMG-box). The current research shows that the SOX gene is widely involved in the processes of embryonic development, sex determination, organogenesis, tumorigenesis and the like. SOX30(SRY box containing gene 30) is the only member of the H subfamily of the SOX gene family, which has a very important role in spermatogenesis.
Obtaining a clinical sample: 15 cases of normal spermatogenic OA puncture testicle tissues of the large-plateau hospital and 58 cases of NOA puncture testicle tissues with detailed pathological information are selected as liquid nitrogen preservation tissues and paraffin specimen tissues, wherein white slices of the paraffin specimen are cut and stored in a refrigerator at 4 ℃. Wherein, the OA inclusion standard is that the tissue morphology is normal, the testicle tissue is punctured to be spermatogenic and normal, and a child can be born by an assisted reproduction means (all detection indexes are the same as or similar to those of normal people). NOA inclusion criteria were determined for patients with NOA for each index, including morphological, biochemical and pathological tests. In addition, all OA and NOA patients received no adjuvant treatment with hyperacidin, chemotherapy and radiation prior to biopsy.
Test 1
In this test, the methylation state of SOX30 gene in normal control OA and NOA-punctured testis tissue was examined, and NOA disease was diagnosed based on the methylation state of SOX30 gene, and the detailed examination procedure is as follows.
1) Purification and extraction of genomic DNA
DNA of the tissue sample is purified and extracted by using a DNA Purification and extraction Kit (Wizard Genomic DNA Purification Kit, A1125) from Promega corporation, the specific operation of which is a technique commonly used in the art and will not be described herein.
2) methylation modification of tissue DNA
The specific operation of the method, which is a technique commonly used in the art, is to perform Methylation modification on the tissue sample DNA by using a Methylation-modification Kit (EZ DNA Methylation-Gold Kit, D5005) of Zymo-Research corporation, and is not described herein again.
3) Methylation analysis (MSP) in modified DNA
MSP primer sequences during methylation analysis are shown in Table 1.
Table 1 shows MSP primer sequences
in Table 1, U denotes an unmethylated primer and M denotes a methylated primer.
In the methylation analysis process, the MSP analysis reaction system is as follows: deionized water 7.5. mu.L, 2xTaq mixture 10. mu.L, upstream primer/F0.5. mu.L, downstream primer/R0.5. mu.L, modified DNA 1.5. mu.L.
In the methylation analysis process, the MSP analysis reaction conditions are as follows: 95 ℃ for 3min, (95 ℃ for 35s, 60 ℃ for 35s, 72 ℃ for 1min) x38, 72 ℃ for 10min, 12 ℃ for 2 h.
In the methylation analysis process, the electrophoresis and statistics process of the MSP product is as follows: the PCR amplification products for MSP analysis were electrophoresed in 2.5% EB-containing agarose gel, photographed and statistically analyzed.
4) Results of methylation analysis
The 5 cases of OA patients puncturing testis tissues and 5 cases of NOA patients puncturing testis tissues, of which the indexes are close to the normal human testis form and pathology, are selected to be respectively subjected to whole genome methylation sequencing, and comparative analysis and chromosome walking analysis show that the SOX30 Gene (Pubmed, Gene ID number: NM-178424) presents the most obvious hypermethylation state in the NOA puncturing testis tissues, as shown in figure 1. The analysis result shows that the methylation of the SOX30 gene in the NOA puncture testis tissue is a specific characteristic event.
In summary, in this experiment, MSP (Methylation-Specific PCR) was performed in randomly selected OA and NOA patients by designing SOX30 Methylation primers (primer sequences are shown in Table 1) by online methprimer based on the SOX30 Methylation sequencing position and puncturing testis tissue by OA and NOA patients (reaction system, conditions and electrophoresis statistics are as described above). The results in FIG. 2 show that SOX30 was significantly methylated in NOA-spiked testis tissue, but not in OA-spiked testis tissue. By analyzing the incidence of SOX30 methylation in punctured testis tissue from 15 control OA and 58 NOA patients, table 2 is the SOX30 methylation incidence analysis table, and as shown in table 2, SOX30 is methylated only in 6.67% (1/15) OA but in as much as 91.38% (53/58) NOA, and this methylation incidence is significantly different between OA and NOA. The data in table 2 further illustrate that SOX30 methylation is a specific important characteristic event in NOAs.
TABLE 2 SOX30 methylation incidence analysis table
Test 2
In this test, expression levels of mRNA and encoded protein in normal control OA and NOA-punctured testis tissues were detected, and NOA disease was diagnosed based on the expression level of SOX30, and the specific detection process is shown below.
1) extraction of tissue total RNA
The extraction of total RNA of the tissue is carried out by using a classical RNA extraction reagent Trizol, and the extraction process is a common technology in the field and will not be described in detail herein.
2) reverse transcription of tissue RNA into cDNA
The specific operation of Reverse Transcription of RNA treated with DNase I (Deoxyribonuclease I) into cDNA using a Reverse Transcription kit (GoScript Reverse Transcription System, A5001) from Promega is a common technique in the art and is not described herein.
3) Reverse transcription-PCR
RT-PCR primer sequences during reverse transcription-PCR (RT-PCR) are shown in Table 3.
TABLE 3 RT-PCR primer sequences
The RT-PCR system during reverse transcription-PCR (RT-PCR) is shown in Table 4.
TABLE 4 RT-PCR System
The RT-PCR reaction conditions are as follows: pre-denaturation at 95 ℃ for 2min, (denaturation at 95 ℃ for 35s, annealing at 60 ℃ for 30s, and extension at 72 ℃ for 1.0min) x35, extension at 72 ℃ for 10min, and sample preservation at 12 ℃.
4) PCR product electrophoresis and statistics
The RT-PCR product was added to 3.0% agarose gel containing EB dye for electrophoresis, observation, photography and statistical analysis.
5) Immunohistochemical (IHC) staining
Conventional tissue fixing, embedding and slicing, baking, hydrating, antigen repairing, enzyme eliminating, serum sealing, antibody incubating, DAB coloring, differentiating and turning blue, sealing, microscopic examination, photographing and statistical analysis.
6) Results of analysis of SOX30 mRNA and protein expression levels
To determine whether SOX30 methylation affects its expression and the altered profile of SOX30 expression in NOA, this experiment examined the mRNA expression of SOX30 in the spiked testis tissue of randomly selected OA and NOA patients as described above by RT-PCR using Actin (Actin) as an internal reference for PCR, with the results shown in FIG. 3 for the silencing of SOX30 expression in NOA patients who were methylated and the normal expression of SOX30 in OA patients who were not methylated. FIG. 4 shows the expression changes of SOX30 protein in OA and NOA patients analyzed by immunohistochemistry, and the results in FIG. 4 show that SOX30 protein is also silenced in NOA patients. The results of the above tests show that SOX30 methylation is closely related to the silencing of its expression.
In order to determine the expression change characteristics of SOX30 in NOA, the test analyzes the expression change of SOX30 in the punctured testis tissues of the same 15 cases of control OA and 58 cases of NOA patients through IHC, the detection results are shown in Table 5, the expression of SOX30 in 15 cases of control OA is positive, the expression of SOX30 in 17.24% (10/58) of NOA is positive, and the positive expression rate of SOX30 in OA and NOA is obviously different. The results of the above tests show that inactivation of SOX30 expression is also a specific important characteristic event in NOA.
TABLE 5 expression of SOX30 protein in OA and NOA-punctured testis tissue
According to the detection results of the test 1 and the test 2, the methylation or expression inactivation of the SOX30 has important significance in the formation of the NOA and is a specific important characteristic event of the NOA. Therefore, whether the azoospermia patient belongs to the NOA patient or not can be judged rapidly by detecting the methylation or expression state of the SOX30 in the punctured testis of the azoospermia patient, and the clinical azoospermia patient is helped to make a treatment scheme faster and better, so that the accuracy is improved, and the early treatment is carried out.
Based on the above detection results, the present application provides a diagnostic kit for non-obstructive azoospermia, comprising a reagent a for detecting the methylation state of SOX30 gene, wherein the reagent a comprises a reagent a1 and a reagent a2, wherein the reagent a1 is used for amplifying a methylation product, the reagent a1 comprises a pair of methylation primers, and the primer sequences of the methylation primers are respectively:
SOX30F-M:TGG GTA GTA GTT ATG GAG TTT TTT TC，
SOX30R-M:CTC TAA CTT CAC CTA CAA CAA CCG；
The reagent A2 is used for amplifying unmethylated products, and the reagent A2 comprises a pair of unmethylated primers, wherein the primer sequences of the unmethylated primers are respectively:
SOX30F-U:TGG GTA GTA GTT ATG GAG TTT TTT TT，
SOX30R-U:CTC TAA CTT CAC CTA CAA CAA CCA C。
In this example, the diagnostic kit further comprises a reagent B, wherein the reagent B is a primer pair for detecting the expression level of the gene SOX30, and the primer sequences of the primer pair are respectively as follows:
SOX30F:GAT GTC CCG CTC ACC GTG TTG C,
SOX30R:GAC AGG GCT TGG GCT CTG GAC T。
In this example, the diagnostic kit further comprises a reagent C, which is a reagent for detecting the content of SOX30 protein.
In this example, reagent C is a monoclonal antibody to the SOX30 protein.
In order to facilitate a better understanding of the present technical solution by the person skilled in the art, the following further description is given in connection with the use of the diagnostic kit for non-obstructive azoospermia of the present application.
Performing genome DNA purification extraction and methylation modification on a patient puncture testicular tissue by a conventional technology, performing RT-PCR amplification on the patient puncture testicular tissue and a reagent A, wherein an amplification system and conditions are shown in test 1, performing electrophoresis in agarose gel and analyzing results, and judging that the patient is an NOA patient when a methylation product (reflected as a strip in the agarose gel electrophoresis) is amplified by the reagent A1; when only reagent A2 amplified non-methylated products (as reflected as bands in agarose gel electrophoresis), the patient was judged to be a non-NOA patient.
Of course, the patient may be punctured with testis tissue (fresh) by conventional techniques to extract total RNA, reverse transcribing into cDNA, and performing RT-PCR amplification with reagent B, where the amplification system and conditions are shown in test 2, and the result of electrophoresis analysis in agarose gel is judged that the patient is NOA patient when reagent B cannot amplify the product (the product is reflected as a band in agarose gel electrophoresis).
of course, the patient may be subjected to immunohistochemical staining analysis by puncturing a paraffin section of the testis tissue, and when the expression of the reagent C is negative, the patient is judged to be NOA patient.
In addition, the reagent A, the reagent B and the reagent C are simultaneously detected when the patient punctures the testicle tissue, so that the accuracy of the NOA judgment result is greatly improved.
in the application, the methylation state of the SOX30 gene, the expression level of mRNA and encoded protein in normal control OA and NOA puncture testis tissues are detected, and the detection result shows that the SOX30 gene is subjected to specific hypermethylation and expression silencing in the NOA puncture testis tissues. Based on the above detection results, the present application provides a diagnostic kit for non-obstructive azoospermia, which is used for rapid diagnosis of NOA diseases, and can rapidly and accurately identify the NOA diseases by specifically detecting the methylation or expression change of the gene SOX30, i.e., detecting the methylation or expression level of the gene. The diagnosis box for the non-obstructive azoospermia can help clinical NOA patients to make an effective treatment scheme, so that accuracy and treatment progress are improved, and meanwhile, the diagnosis box has important significance in better understanding NOA pathogenic reasons, making risk assessment and early diagnosis.
It should be noted that hypermethylation in this application means that SOX30 methylation is higher in NOA-spiked testis than in OA-spiked testis; the expression silencing means that SOX30 mRNA and protein are not expressed or are far less expressed than OA puncture testis in NOA puncture testis.
The above-described embodiments of the present application do not limit the scope of the present application.
Claims (4)
1. A diagnostic kit for non-obstructive azoospermia, comprising a reagent A for detecting the methylation state of the SOX30 gene,
The reagent A comprises a reagent A1 and a reagent A2, wherein the reagent A1 is used for amplifying a methylation product, and the reagent A1 comprises a pair of methylation primers, and the primer sequences of the methylation primers are respectively as follows:
SOX30F-M:TGG GTA GTA GTT ATG GAG TTT TTT TC，
SOX30R-M:CTC TAA CTT CAC CTA CAA CAA CCG；
the reagent A2 is used for amplifying unmethylated products, and the reagent A2 comprises a pair of unmethylated primers, wherein the primer sequences of the unmethylated primers are respectively:
SOX30F-U:TGG GTA GTA GTT ATG GAG TTT TTT TT，
SOX30R-U:CTC TAA CTT CAC CTA CAA CAA CCA C。
2. The diagnostic kit for non-obstructive azoospermia according to claim 1, further comprising a reagent B, which is a primer pair for detecting the expression level of gene SOX30, the primer sequences of the primer pair are respectively:
SOX30F:GAT GTC CCG CTC ACC GTG TTG C,
SOX30R:GAC AGG GCT TGG GCT CTG GAC T。
3. The diagnostic kit for non-obstructive azoospermia according to claim 1, further comprising a reagent C, which is a reagent for detecting the content of SOX30 protein.
4. The diagnostic kit for non-obstructive azoospermia according to claim 3, wherein the reagent C is a monoclonal antibody to the SOX30 protein.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910897201.9A CN110577991B (en) | 2019-09-23 | 2019-09-23 | Diagnosis box for non-obstructive azoospermia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910897201.9A CN110577991B (en) | 2019-09-23 | 2019-09-23 | Diagnosis box for non-obstructive azoospermia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110577991A true CN110577991A (en) | 2019-12-17 |
| CN110577991B CN110577991B (en) | 2022-05-27 |
Family
ID=68813324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910897201.9A Active CN110577991B (en) | 2019-09-23 | 2019-09-23 | Diagnosis box for non-obstructive azoospermia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110577991B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2107127A1 (en) * | 2008-03-31 | 2009-10-07 | Université Joseph Fourier | In vitro diagnostic method for the diagnosis of somatic and ovarian cancers |
| CN108828228A (en) * | 2018-05-23 | 2018-11-16 | 远见生物科技（上海）有限公司 | Prediction or NANOS2 marker and its application of diagnosis azoospermatism or aspermia or oligospermia |
-
2019
- 2019-09-23 CN CN201910897201.9A patent/CN110577991B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2107127A1 (en) * | 2008-03-31 | 2009-10-07 | Université Joseph Fourier | In vitro diagnostic method for the diagnosis of somatic and ovarian cancers |
| CN108828228A (en) * | 2018-05-23 | 2018-11-16 | 远见生物科技（上海）有限公司 | Prediction or NANOS2 marker and its application of diagnosis azoospermatism or aspermia or oligospermia |
Non-Patent Citations (4)
| Title |
|---|
| DAOQIN ZHANG等: "The transcription factor SOX30 is a key regulator of mouse spermiogenesis", 《DEVELOPMENT》, vol. 145, no. 11, 30 May 2018 (2018-05-30), pages 164723 * |
| FEIHAN等: "Epigenetic Inactivation of SOX30 Is Associated with Male Infertility and Offers a Therapy Target for Non-obstructive Azoospermia", 《MOL THER NUCLEIC ACIDS》, vol. 19, 14 November 2019 (2019-11-14), pages 72 - 83 * |
| 马学翔: "Sox30基因在小鼠和大鼠睾丸发育过程中的表达与甲基化分析", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》, no. 06, 15 June 2016 (2016-06-15), pages 059 - 18 * |
| 马学翔等: "Sox30基因在大鼠睾丸发育中的表达与甲基化分析", 《实用临床医药杂志》, no. 01, 8 January 2016 (2016-01-08), pages 5 - 8 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110577991B (en) | 2022-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8927209B2 (en) | Liver cancer methods and compositions | |
| US20190136330A1 (en) | Method for screening cancer | |
| US9598735B2 (en) | Detection of a panel of urine DNA markers for HCC screening and disease management | |
| CN109504780B (en) | DNA methylation qPCR kit for lung cancer detection and use method thereof | |
| CN113846167B (en) | Molecular marker detection kit for primary liver cancer, nucleic acid composition and application | |
| JP2009106191A (en) | Gene associated with liver cancer, and method for determination of risk of acquiring liver cancer | |
| CN116814781A (en) | Markers, kits and devices for detecting urothelial cancer | |
| Ramezanzadeh et al. | Detection of paternally inherited fetal point mutations for β-thalassemia in maternal plasma using simple fetal DNA enrichment protocol with or without whole genome amplification: an accuracy assessment | |
| EP4144859A1 (en) | Tumor detection reagent and kit | |
| CN110577991B (en) | Diagnosis box for non-obstructive azoospermia | |
| WO2024192928A1 (en) | Gene combination for liver cancer detection, and related reagent and application | |
| CN106967792B (en) | DKK-3 gene methylation diagnostic reagent system, kit and application thereof | |
| CN113046437A (en) | Method for detecting MET E14 jump mutation | |
| CN109439750B (en) | Molecular marker for detecting susceptibility of cervical cancer, kit and application | |
| US20130288918A1 (en) | Colorectal Cancer Screening Method | |
| CN115992212A (en) | UBE3A mutant protein, UBE3A gene mutant, amplification primer, detection reagent and application | |
| CN109321658B (en) | Kit for detecting susceptibility of cervical cancer | |
| CN105779612A (en) | Lynch syndrome gene detection reagent kit and application thereof | |
| NZ584815A (en) | 3.4 kb mitochondrial dna deletion for use in the detection of cancer | |
| CN110408693A (en) | The new application of LOC105373033 | |
| CN114317744B (en) | Application of reagent for detecting SNP locus polymorphism in screening cervical cancer | |
| CN118147311B (en) | Methylation marker kit for urothelial cancer | |
| CN114606311B (en) | Application of SLC39A13 gene rs755555 locus, detection primer and probe combination thereof and kit | |
| CN108866189B (en) | Kit and system for predicting susceptibility of squamous cell carcinoma of larynx | |
| CN116622851A (en) | DNA methylation composition for detecting liver cancer, kit and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |